EUVIMEDEUVIMED entdecken
Open Access

Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease

Piergiorgio Grillo iD, Luis Concha-Marambio iD, Antonio Pisani iD, Giulietta Maria Riboldi iD, Un Jung Kang iD

Movement Disorders · 2025

DOI: 10.1002/mds.30085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2025. Verfasst von Piergiorgio Grillo und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, Department of Neurology, NYU Langone Health, New York City, New York, …. Hauptthemen laut MEDLINE: Parkinson Disease, alpha-Synuclein. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS, The Marlene and Paolo Fresco Institute Post-doctoral Clinical Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background α‐Synuclein seed amplification assay on cerebrospinal fluid (CSF‐αSyn‐SAA) has shown high accuracy for Parkinson's disease (PD) diagnosis. The analysis of CSF‐αSyn‐SAA parameters may provide useful insight to dissect the heterogeneity of synucleinopathies.

Objective

To assess differences in CSF‐αSyn‐SAA amplification parameters in participants with PD stratified by rapid eye movement (REM) sleep behavior disorder (RBD), dysautonomia, GBA , and LRRK2 variants.

Methods

Clinical and CSF‐αSyn‐SAA data from the Parkinson's Progression Marker Initiative dataset were used. CSF‐αSyn‐SAA parameters included maximum fluorescence (F max ), time to reach 50% of F max (T50), time to threshold (TTT), slope, and area under the curve (AUC). Sporadic PD (n = 371) was stratified according to RBD and dysautonomia (DysA) symptoms. Genetic PD included carriers of pathogenic variants of GBA ( GBA ‐PD, n = 52) and LRRK2 ( LRRK2 ‐PD, n = 124) gene.

Results

CSF‐αSyn‐SAA was positive in 77% of LRRK2 ‐PD, 92.3% of GBA ‐PD, and 93.8% of sporadic PD. The LRRK2 ‐PD cohort showed longer T50 and TTT, and smaller AUC than GBA ‐PD ( P = 0.029, P = 0.029, P = 0.016, respectively) and sporadic PD ( P = 0.034, P = 0.033, P = 0.014, respectively). In the sporadic cohort, CSF‐αSyn‐SAA parameters were similar between PD with (n = 157) and without (n = 190) RBD, whereas participants with DysA (n = 193) presented shorter T50 ( P = 0.026) and larger AUC ( P = 0.029) than those without (n = 150).

Conclusion

CSF‐αSyn‐SAA parameters vary across genetic and non‐genetic PD subtypes at the group level. These differences are mostly driven by the presence of LRRK2 variants and DysA. Significant overlaps in the amplification parameter values exist between groups and limit their use at the individual level. Further studies are necessary to understand the mechanisms of CSF‐αSyn‐SAA parameter differences. © 2024 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson Diseasealpha-SynucleinHumansMaleFemaleLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Middle AgedAgedREM Sleep Behavior DisorderPrimary DysautonomiasBiomarkersGlucosylceramidase

Stichwörter der Autor:innen

GBA1LRRK2Parkinson's diseaseRBDα‐synuclein seed amplification assay

Substanzen

alpha-SynucleinLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanGBA protein, humanSNCA protein, humanBiomarkersGlucosylceramidase

Autor:innen und Institutionen

  • The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, Department of Neurology, NYU Langone Health, New York City, New York, USA.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
  • IRCCS Mondino Foundation, Pavia, Italy.
  • Amprion, R&D Unit, San Diego, California, USA.
  • Department of Neuroscience and Physiology, Neuroscience Institute, Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York City, New York, USA.

ORCID-Profile: Piergiorgio Grillo, Luis Concha-Marambio, Antonio Pisani, Giulietta Maria Riboldi, Un Jung Kang

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • The Marlene and Paolo Fresco Institute Post-doctoral Clinical Fellowship
  • NEXTGENERATIONEU (NGEU)
  • Michael J Fox Foundation, Parkinson's Foundation, Department of Defense
  • Ministry of University and Research (MUR)
  • National Recovery and Resilience Plan (NRRP)
  • National Institutes of Health

Zitieren

APA

Grillo, P., Concha-Marambio, L., Pisani, A., Riboldi, G. M., & Kang, U. J. (2025). Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease. Movement Disorders. https://doi.org/10.1002/mds.30085

Vancouver

Grillo P, Concha-Marambio L, Pisani A, Riboldi GM, Kang UJ. Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease. Movement Disorders. 2025. doi:10.1002/mds.30085

BibTeX
@article{Grillo2025,
  author = {Grillo, Piergiorgio and Concha-Marambio, Luis and Pisani, Antonio and Riboldi, Giulietta Maria and Kang, Un Jung},
  title = {Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease},
  journal = {Movement Disorders},
  year = {2025},
  doi = {10.1002/mds.30085}
}
Kostenlos starten →